S'abonner

Metabolome subtyping of severe bronchiolitis in infancy and risk of childhood asthma - 05/01/22

Doi : 10.1016/j.jaci.2021.05.036 
Zhaozhong Zhu, ScD a, , Carlos A. Camargo, MD, DrPH a, Yoshihiko Raita, MD, MPH, MMSc a, Michimasa Fujiogi, MD a, Liming Liang, PhD b, c, Eugene P. Rhee, MD d, Prescott G. Woodruff, MD, MPH e, Kohei Hasegawa, MD, MPH a
a Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 
b Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Mass 
c Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Mass 
d Nephrology Division and Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 
e Division of Pulmonary and Critical Care Medicine, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, Calif 

Corresponding author: Zhaozhong Zhu, ScD, Department of Emergency Medicine, Massachusetts General Hospital, 125 Nashua Street, Suite 920, Boston, MA 02114.Department of Emergency MedicineMassachusetts General Hospital125 Nashua StreetSuite 920BostonMA02114

Abstract

Background

Infants with bronchiolitis are at increased risk for developing asthma. Growing evidence suggests bronchiolitis is a heterogeneous condition.

Objectives

We sought to identify biologically distinct subgroups based on the metabolome signatures (metabotypes) in infants with severe bronchiolitis and to examine the longitudinal relationships of metabotypes with asthma development.

Methods

In a multicenter prospective cohort study of infants (age, <12 months) hospitalized for bronchiolitis, the nasopharyngeal airway metabolome was profiled at hospitalization. Using a clustering approach, this study identified mutually exclusive metabotypes. This study also examined their longitudinal association with the risk of developing asthma by 5 years of age.

Results

Of 918 infants hospitalized for bronchiolitis (median age, 3 months), this study identified 5 distinct metabotypes—characterized by their nasopharyngeal metabolome profile: A, glycerophosphocholine-high; B, amino acid–high, polyunsaturated fatty acid–low; C, amino acid–high, glycerophospholipid-low; D, glycerophospholipid-high; and E, mixed. Compared with infants with metabotype A (who clinically resembled “classic” bronchiolitis), infants with metabotype B had a significantly higher risk for developing asthma (23% vs 41%; adjusted odds ratio, 2.22; 95% CI, 1.07-4.69). The pathway analysis showed that metabotype B had enriched amino acid (eg, methionine, histidine, glutathione) and α-linolenic/linoleic acid metabolism pathways (false discovery rate, <5 × 10−14 for all). Finally, the transcriptome analysis revealed that infants with metabotype B had upregulated IFN-α and IL-6/JAK/STAT3 pathways and downregulated fatty acid metabolism pathways (false discovery rate, <0.05 for both).

Conclusions

In this multicenter prospective cohort study of infants with severe bronchiolitis, the clustering analysis of metabolome data identified biologically distinct metabotypes, including a metabotype characterized by high inflammatory amino acids and low polyunsaturated fatty acids that is at significantly increased risk for developing asthma.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Severe bronchiolitis, heterogeneity, subtype, asthma, metabolome, inflammatory amino acids, polyunsaturated fatty acids, transcriptome

Abbreviations used : FDR, GP, HODE, HRadj, OR, PUFA


Plan


 This study was supported by the National Institutes of Health (grants K01 AI-153558, U01 AI-087881, R01 AI-114552, R01 AI-127507, R01 AI-134940, R01 AI-137091, R01 AI-148338, and UG3/UH3 OD-023253). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding organizations were not involved in the collection, management, or analysis of the data; preparation or approval of the manuscript; or decision to submit the manuscript for publication.
 Disclosure of potential conflict of interest: Z. Zhu reports grants from National Institutes of Health during the conduct of the study. C. A. Camargo reports grants from National Institutes of Health during the conduct of the study. P. G. Woodruff reports personal fees from Sanofi, Regeneron, Astra Zeneca, Glenmark Pharma, Theravance, NGM Pharma, and GSK, outside the submitted work. K. Hasegawa reports grants from National Institutes of Health during the conduct of the study; and grants from Novartis, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.


© 2021  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 149 - N° 1

P. 102-112 - janvier 2022 Retour au numéro
Article précédent Article précédent
  • Mapping atopic dermatitis and anti–IL-22 response signatures to type 2–low severe neutrophilic asthma
  • Yusef Eamon Badi, Ana B. Pavel, Stelios Pavlidis, John H. Riley, Stewart Bates, Nazanin Zounemat Kermani, Richard Knowles, Johan Kolmert, Craig E. Wheelock, Sally Worsley, Mohib Uddin, Kjell Alving, Per S. Bakke, Annelie Behndig, Massimo Caruso, Pascal Chanez, Louise J. Fleming, Stephen J. Fowler, Urs Frey, Peter Howarth, Ildikó Horváth, Norbert Krug, Anke H. Maitland-van der Zee, Paolo Montuschi, Graham Roberts, Marek Sanak, Dominick E. Shaw, Florian Singer, Peter J. Sterk, Ratko Djukanovic, Sven-Eric Dahlen, Yi-Ke Guo, Kian Fan Chung, Emma Guttman-Yassky, Ian M. Adcock, U-BIOPRED Study Group
| Article suivant Article suivant
  • Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation
  • Marc Gauthier, Sagar Laxman Kale, Timothy B. Oriss, Kathryn Scholl, Sudipta Das, Huijuan Yuan, Sanmei Hu, Jie Chen, Matthew Camiolo, Prabir Ray, Sally Wenzel, Anuradha Ray

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.